JP7372026B2 - 炎症および線維症のペプチド治療 - Google Patents

炎症および線維症のペプチド治療 Download PDF

Info

Publication number
JP7372026B2
JP7372026B2 JP2017559043A JP2017559043A JP7372026B2 JP 7372026 B2 JP7372026 B2 JP 7372026B2 JP 2017559043 A JP2017559043 A JP 2017559043A JP 2017559043 A JP2017559043 A JP 2017559043A JP 7372026 B2 JP7372026 B2 JP 7372026B2
Authority
JP
Japan
Prior art keywords
lys
asp
peptide
ebpβ
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017559043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520999A5 (enExample
JP2018520999A (ja
Inventor
チョキエール，マリオ
バック，マルティナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2018520999A publication Critical patent/JP2018520999A/ja
Publication of JP2018520999A5 publication Critical patent/JP2018520999A5/ja
Application granted granted Critical
Publication of JP7372026B2 publication Critical patent/JP7372026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017559043A 2015-05-12 2016-04-11 炎症および線維症のペプチド治療 Active JP7372026B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160173P 2015-05-12 2015-05-12
US62/160,173 2015-05-12
PCT/US2016/026966 WO2016182660A1 (en) 2015-05-12 2016-04-11 Peptide treatment for inflammation and fibrosis

Publications (3)

Publication Number Publication Date
JP2018520999A JP2018520999A (ja) 2018-08-02
JP2018520999A5 JP2018520999A5 (enExample) 2021-02-25
JP7372026B2 true JP7372026B2 (ja) 2023-10-31

Family

ID=57248348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017559043A Active JP7372026B2 (ja) 2015-05-12 2016-04-11 炎症および線維症のペプチド治療

Country Status (7)

Country Link
US (1) US10434134B2 (enExample)
EP (1) EP3294752B1 (enExample)
JP (1) JP7372026B2 (enExample)
CN (3) CN114181281A (enExample)
AU (1) AU2016260190A1 (enExample)
CA (1) CA2984769C (enExample)
WO (1) WO2016182660A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016260190A1 (en) * 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
RU2019123160A (ru) * 2016-12-29 2021-01-29 Юниверсити Оф Майами Способ модуляции активности инфламмасом и воспаления в легком
SG11202013176VA (en) 2018-07-03 2021-01-28 Univ Miami Compositions and methods for treating inflammasome related diseases or conditions
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
CN111770539B (zh) 2019-04-02 2021-07-09 大唐移动通信设备有限公司 一种lmf选择方法、终端定位服务方法及装置
WO2021101966A1 (en) * 2019-11-18 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
CN114134191B (zh) * 2020-09-04 2023-12-12 琛蓝(美国)营养制品股份有限公司 一种抗炎护肾的蛤蜊肽的制备方法和应用
CN112960780B (zh) * 2021-03-03 2023-02-03 龙江环保集团股份有限公司 一种生物膜载体的预处理方法及生物法污水处理工艺
DE102022203153A1 (de) 2022-03-31 2023-10-05 Psa Automobiles Sa Stauraumanordnung für einen Innenraum eines Fahrzeugs, Fahrzeug mit der Stauraumanordnung und Verfahren zur Benutzung einer Stauraumanordnung
KR102772405B1 (ko) * 2022-06-10 2025-02-26 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도
CN115850440B (zh) * 2022-12-09 2023-07-11 中国人民解放军陆军军医大学 一种长链MyD88诱饵肽及其作为药物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035825A1 (en) 2000-10-27 2010-02-11 Mario Chojkier Treatment Of Disease By Inducing Cell Apoptosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
WO2002054938A2 (en) * 2000-10-27 2002-07-18 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
CN1678336A (zh) * 2002-02-21 2005-10-05 加州大学校务委员会 用细胞凋亡诱导方法治疗疾病
US7119071B2 (en) * 2002-05-21 2006-10-10 University Of Medicine And Dentistry Of New Jersey Amino terminal substance P compositions and methods for using the same
MX2007013430A (es) * 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US8865657B2 (en) * 2005-08-19 2014-10-21 New York University Compositions and methods for inactivating or suppressing inflammatory cells
EP2324048A2 (en) * 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
HK1198333A1 (zh) * 2011-07-19 2015-04-02 Thrasos Innovation, Inc. 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途
CA2864100A1 (en) * 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
AU2016260190A1 (en) * 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035825A1 (en) 2000-10-27 2010-02-11 Mario Chojkier Treatment Of Disease By Inducing Cell Apoptosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＰＬｏｓ ＯＮＥ，２０１１年，Ｖｏｌ．６，Ｎｏ．１０，ｅ２５４９７，ｐｐ．１－１８

Also Published As

Publication number Publication date
CN114621318A (zh) 2022-06-14
CA2984769C (en) 2023-03-21
JP2018520999A (ja) 2018-08-02
CN107531752A (zh) 2018-01-02
US20180125919A1 (en) 2018-05-10
CA2984769A1 (en) 2016-11-17
EP3294752B1 (en) 2020-11-04
NZ736840A (en) 2024-05-31
AU2016260190A1 (en) 2017-11-23
EP3294752A1 (en) 2018-03-21
US10434134B2 (en) 2019-10-08
CN107531752B (zh) 2022-05-10
WO2016182660A1 (en) 2016-11-17
EP3294752A4 (en) 2018-12-19
CN114181281A (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
JP7372026B2 (ja) 炎症および線維症のペプチド治療
JP6676589B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
ES2901477T3 (es) Nuevos análogos de urocortina-2 modificados con ácidos grasos para el tratamiento de la diabetes y la enfermedad renal crónica
CA2796174C (en) Peptide derivatives, preparation thereof and uses thereof
JP6084207B2 (ja) 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤
CN103476933B (zh) 白介素1受体的拮抗剂
ES2349743T3 (es) Derivados de la il-21.
JP2014510758A (ja) ほ乳類において脂肪細胞を標的とするための方法および組成物
JP7778301B2 (ja) Ｒｅｇｎａｓｅ－１が関与する疾患の治療および／または予防方法
KR20230121824A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
KR20230121822A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
KR102419584B1 (ko) 혈액뇌장벽 투과 펩타이드를 유효성분으로 포함하는 조성물 및 이의 용도
KR102415717B1 (ko) 혈액뇌장벽 투과능을 가지는 신규한 펩타이드 및 이의 용도
WO2017073764A1 (ja) 新規ｎｋ３受容体アゴニスト
US11351227B2 (en) Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
ES2979305T3 (es) Composiciones y métodos para tratar enfermedades metabólicas
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
HK40076050A (en) Peptide treatment for inflammation and fibrosis
US20240002441A1 (en) Peptides and uses thereof in modulation of amyloid-beta protein degrading proteases
US20240174728A1 (en) A use of a polypeptide compound in the preparation of drugs for preventing or treating inflammatory bowel diseases and related intestinal fibrosis
US20180134763A1 (en) Brain penetrant amylin receptor based peptides for alzheimer's disease
Lee Stromal Cell-Derived Factor-1 Retention and Cardioprotection for Ischemic Myocardium
KR20230038600A (ko) 폐내 염증의 완화
HK1191025A (en) Inhibitors of apoptosis and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201026

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210909

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210915

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211018

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211019

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211029

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211102

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220816

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230124

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231019

R150 Certificate of patent or registration of utility model

Ref document number: 7372026

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150